Is FLGT or XGN more profitable?

Fulgent Genetics has a net margin of -23.04% compared to Exagen's net margin of -29.49%. Fulgent Genetics' return on equity of -3.24% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -23.04% -3.24% -2.97% Exagen -29.49% -94.37% -28.96%

Does the media favor FLGT or XGN?

In the previous week, Fulgent Genetics had 2 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for Exagen. Exagen's average media sentiment score of 0.00 beat Fulgent Genetics' score of -0.04 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate MCTA or XGN?

Exagen has a consensus target price of $9.25, indicating a potential upside of 115.62%. Given Exagen's stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has preferable earnings and valuation, MCTA or XGN?

Charming Medical has higher earnings, but lower revenue than Exagen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charming Medical N/A N/A N/A N/A N/A Exagen $66.57M 1.56 -$19.95M -$0.89 N/A

Does the media favor MCTA or XGN?

In the previous week, Charming Medical had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Charming Medical and 1 mentions for Exagen. Charming Medical's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charming Medical 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XGN or TOI?

In the previous week, Oncology Institute had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Oncology Institute and 1 mentions for Exagen. Oncology Institute's average media sentiment score of 1.46 beat Exagen's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncology Institute 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XGN or AIRS?

In the previous week, AirSculpt Technologies had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for AirSculpt Technologies and 1 mentions for Exagen. AirSculpt Technologies' average media sentiment score of 0.21 beat Exagen's score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AirSculpt Technologies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend XGN or VMD?

Exagen currently has a consensus target price of $9.25, indicating a potential upside of 115.62%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, XGN or VMD?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.56 -$19.95M -$0.89 N/A Viemed Healthcare $270.28M 1.41 $14.93M $0.37 26.95

Does the media refer more to XGN or VMD?

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled Viemed Healthcare'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viemed Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Exagen (XGN) Competitors

$4.29 -0.50 (-10.44%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$4.28 -0.01 (-0.23%)

As of 06/5/2026 05:35 PM Eastern

Compare

XGN vs. FLGT, MCTA, TOI, AIRS, and VMD

Should you buy Exagen stock or one of its competitors? MarketBeat compares Exagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exagen include Fulgent Genetics (FLGT), Charming Medical (MCTA), Oncology Institute (TOI), AirSculpt Technologies (AIRS), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.

How does Exagen compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Fulgent Genetics currently has a consensus target price of $27.00, suggesting a potential upside of 40.99%. Exagen has a consensus target price of $9.25, suggesting a potential upside of 115.62%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Fulgent Genetics has a net margin of -23.04% compared to Exagen's net margin of -29.49%. Fulgent Genetics' return on equity of -3.24% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Exagen	-29.49%	-94.37%	-28.96%

Exagen has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.69	-$60.51M	-$2.39	N/A
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A

Fulgent Genetics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Fulgent Genetics had 2 more articles in the media than Exagen. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for Exagen. Exagen's average media sentiment score of 0.00 beat Fulgent Genetics' score of -0.04 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Exagen beats Fulgent Genetics on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Charming Medical has a net margin of 0.00% compared to Exagen's net margin of -29.49%. Charming Medical's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
Exagen	-29.49%	-94.37%	-28.96%

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Charming Medical has higher earnings, but lower revenue than Exagen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A

In the previous week, Charming Medical had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Charming Medical and 1 mentions for Exagen. Charming Medical's average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charming Medical	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exagen has a consensus target price of $9.25, indicating a potential upside of 115.62%. Given Exagen's stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Exagen beats Charming Medical on 6 of the 10 factors compared between the two stocks.

How does Exagen compare to Oncology Institute?

Exagen (NASDAQ:XGN) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Oncology Institute had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Oncology Institute and 1 mentions for Exagen. Oncology Institute's average media sentiment score of 1.46 beat Exagen's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncology Institute	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen presently has a consensus price target of $9.25, suggesting a potential upside of 115.62%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 43.74%. Given Exagen's stronger consensus rating and higher probable upside, research analysts clearly believe Exagen is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Exagen has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A
Oncology Institute	$502.73M	0.96	-$60.61M	-$0.37	N/A

Oncology Institute has a net margin of -7.42% compared to Exagen's net margin of -29.49%. Oncology Institute's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Oncology Institute	-7.42%	N/A	-24.68%

75.3% of Exagen shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Summary

Exagen beats Oncology Institute on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to AirSculpt Technologies?

Exagen (NASDAQ:XGN) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Exagen currently has a consensus target price of $9.25, indicating a potential upside of 115.62%. AirSculpt Technologies has a consensus target price of $4.50, indicating a potential downside of 11.94%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

In the previous week, AirSculpt Technologies had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for AirSculpt Technologies and 1 mentions for Exagen. AirSculpt Technologies' average media sentiment score of 0.21 beat Exagen's score of 0.00 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AirSculpt Technologies	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A
AirSculpt Technologies	$151.82M	2.37	-$11.67M	-$0.17	N/A

AirSculpt Technologies has a net margin of -7.39% compared to Exagen's net margin of -29.49%. AirSculpt Technologies' return on equity of -4.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

Summary

AirSculpt Technologies beats Exagen on 12 of the 16 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.56	-$19.95M	-$0.89	N/A
Viemed Healthcare	$270.28M	1.41	$14.93M	$0.37	26.95

Viemed Healthcare has a net margin of 5.20% compared to Exagen's net margin of -29.49%. Viemed Healthcare's return on equity of 10.52% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Viemed Healthcare	5.20%	10.52%	7.60%

Exagen currently has a consensus target price of $9.25, indicating a potential upside of 115.62%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

75.3% of Exagen shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 20.0% of Viemed Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled Viemed Healthcare'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viemed Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Viemed Healthcare beats Exagen on 8 of the 14 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$103.65M	$8.48B	$6.66B	$11.99B
Dividend Yield	N/A	2.52%	2.67%	5.35%
P/E Ratio	-4.82	16.14	24.06	23.63
Price / Sales	1.56	6.93	515.84	112.52
Price / Cash	N/A	17.18	42.23	54.60
Price / Book	5.57	3.56	9.73	6.35
Net Income	-$19.95M	$224.05M	$3.57B	$337.59M
7 Day Performance	-13.86%	-2.11%	-1.28%	-2.52%
1 Month Performance	45.92%	1.23%	1.38%	-0.03%
1 Year Performance	-40.83%	-3.59%	23.93%	25.34%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.461 of 5 stars	$4.29 -10.4%	$9.25 +115.6%	-40.8%	$103.65M	$66.57M	N/A	220	Gap Down
FLGT Fulgent Genetics	2.7179 of 5 stars	$18.70 +3.4%	$27.00 +44.4%	-10.6%	$513.77M	$322.67M	N/A	1,315
MCTA Charming Medical	N/A	$29.36 flat	N/A	N/A	$497.21M	N/A	N/A	49	News Coverage Gap Down High Trading Volume
TOI Oncology Institute	4.4637 of 5 stars	$4.59 -4.0%	$7.00 +52.5%	+75.2%	$472.45M	$502.73M	N/A	660	Positive News
AIRS AirSculpt Technologies	1.375 of 5 stars	$5.22 -1.5%	$4.50 -13.8%	+0.8%	$373.89M	$151.82M	N/A	240	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. FLGT, MCTA, TOI, AIRS, and VMD

How does Exagen compare to Fulgent Genetics?

Summary

How does Exagen compare to Charming Medical?

Summary

How does Exagen compare to Oncology Institute?

Summary

How does Exagen compare to AirSculpt Technologies?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. FLGT, MCTA, TOI, AIRS, and VMD

How does Exagen compare to Fulgent Genetics?

Do analysts rate FLGT or XGN?

Is FLGT or XGN more profitable?

Which has better valuation and earnings, FLGT or XGN?

Which has more risk & volatility, FLGT or XGN?

Do institutionals & insiders hold more shares of FLGT or XGN?

Does the media favor FLGT or XGN?

Summary

How does Exagen compare to Charming Medical?

Is MCTA or XGN more profitable?

Do institutionals & insiders hold more shares of MCTA or XGN?

Which has preferable earnings and valuation, MCTA or XGN?

Does the media favor MCTA or XGN?

Do analysts rate MCTA or XGN?

Summary

How does Exagen compare to Oncology Institute?

Does the media refer more to XGN or TOI?

Do analysts prefer XGN or TOI?

Which has higher earnings & valuation, XGN or TOI?

Is XGN or TOI more profitable?

Do institutionals and insiders have more ownership in XGN or TOI?

Which has more volatility and risk, XGN or TOI?

Summary

How does Exagen compare to AirSculpt Technologies?

Do institutionals and insiders believe in XGN or AIRS?

Do analysts recommend XGN or AIRS?

Which has more risk & volatility, XGN or AIRS?

Does the media refer more to XGN or AIRS?

Which has stronger earnings and valuation, XGN or AIRS?

Is XGN or AIRS more profitable?

Summary

How does Exagen compare to Viemed Healthcare?

Which has stronger earnings and valuation, XGN or VMD?

Is XGN or VMD more profitable?

Do analysts recommend XGN or VMD?

Do institutionals and insiders believe in XGN or VMD?

Does the media refer more to XGN or VMD?

Which has more risk & volatility, XGN or VMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools